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Transcriptional analysis of metastatic uveal melanoma
survival nominates NRP1 as a therapeutic target

Riyue Baoa,b, Oliver Surrigac, Daniel J. Olsond, Jacob B. Allrede,
Carrie A. Strande, Yuanyuan Zhad, Timothy Carlld, Brian W. Labadied,
Bruno R. Bastosf,g, Marcus Butlerh, David Hoggh, Elgilda Music,
Grazia Ambrosinic, Pamela Munsteri, Gary K. Schwartzc and Jason J. Lukea,b
Uveal melanoma is a rare form of melanoma with
particularly poor outcomes in the metastatic setting. In
contrast with cutaneous melanoma, uveal melanoma lacks
BRAF mutations and demonstrates very low response
rates to immune-checkpoint blockade. Our objectives
were to study the transcriptomics of metastatic uveal
melanoma with the intent of assessing gene pathways
and potential molecular characteristics that might be
nominated for further exploration as therapeutic targets.
We initially analyzed transcriptional data from The Cancer
Genome Atlas suggesting PI3K/mTOR and glycolysis
as well as IL6 associating with poor survival. From
tumor samples collected in a prospective phase II trial
(A091201), we performed a transcriptional analysis of
human metastatic uveal melanoma observing a novel role
for epithelial-mesenchymal transition associating with
survival. Specifically, we nominate and describe initial
functional validation of neuropillin-1 from uveal melanoma
cells as associated with poor survival and as a mediator

Introduction

Melanomas arising within the iris, ciliary body, and choroid of the eye make up the rare subset of uveal melanomas with approximately 2500 cases annually in the
United States [1]. Despite aggressive management of
primary uveal melanoma (pUM) with radiation or enucleation, approximately 50% of patients will develop metastasis and this primary disease phenotype is associated
with specific gene expression patterns [2]. Metastasis of
uveal melanoma preferentially develops in the liver and
is thought to be driven by high levels of growth factors
such as epidermal-, insulin-like-, and hepatic growth factors [1]. Survival of patients following metastasis is poor at
6–12 months and the treatment of uveal melanoma has not
benefited by the recent improvements for melanoma more
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broadly [1,3]. Currently, no systemic therapies are associated with an improvement in survival. Therapies such as
immune-checkpoint inhibitors [4,5] and targeted therapies [6] have demonstrated little benefit such that hepatic
tumor embolization remains a default approach [1].
In contrast to cutaneous melanoma where mutations in
BRAF, NRAS, NF1, and KIT genes are hallmarks of disease
[3], pUM rarely if ever harbors these and instead commonly
carries mutations in the G-protein α proteins q (GNAQ) or
11 (GNA11) [7,8]. Activated signaling via GNAQ/GNA11
is mediated through phospholipase C, eventually leading
to outputs of the Yes-associated protein (YAP) [9,10] and
mitogen-activated protein kinase (MAPK) pathway [7]. In
addition to Gα genes, CYSTLR2 [11] and PLCB4 [12] act
in the same pathway but are mutually exclusive with Gα.
Additionally, several other genes have also been identified as recurrently mutated, dysregulated, or over-expressed such as BAP1, SF3B1, and EIF1AX [13].
The molecular biology of uveal melanoma, and associations with survival or treatment outcomes, have been
detailed almost exclusively from pUM samples and
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cell lines derived from them. The most comprehensive description of uveal melanoma biology to date has
been provided from The Cancer Genome Atlas (TCGA)
in which analysis of 80 pUM suggested four molecular
groups defined the presence or absence of chromosomal
monosomy 3 (M3) vs. disomy 3 (D3) [13]. More specifically poor-prognosis M3-UM is associated with BAP1
loss, aberrant DNA methylation, somatic copy number
aberrations, and RNA alterations relative to good-prognosis D3-UM, where alternative genomic and transcriptional changes are observed. Protein-based analyses have
also suggested expression patterns associated with survival in pUM. For example, in a retrospective review of
pUM samples, c-MET expression was associated with a
higher risk of death from metastatic disease [14]. This led
to the rationale for targeting MET kinase therapeutically,
which despite preclinical support [15] was unsuccessful
in a randomized study of cabozantinib as compared with
chemotherapy (A091201) [16]. This experience highlights the need for molecular data associated with outcomes from tumors in the metastatic setting.

patients with uveal melanoma (Supplementary Table 1,
Supplemental digital content 1, http://links.lww.com/MR/
A245) correlating these with survival and performing
differential gene expression based on patient survival.
These data nominate an important role for epithelial-mesenchymal transition (EMT) impacting outcomes
for metastatic disease and nominate neuropilin-1 (NRP1)
as a novel therapeutic target for future translational and
potentially clinical investigation.

An inadequate literature describes the biology of human
uveal melanoma metastases, although some studies have
begun to report somatic mutational landscapes similar
to that described in primary lesions. From a study of 52
metastatic samples obtained in a prospective clinical trial
of metastatic disease [17], massively parallel sequencing
of clinically relevant cancer genes identified mutations
known from pUM within TCGA [13] and other databases [12] including GNAQ, GNA11, BAP1, PLCB4, and
amplification of chromosome arm 8q. An analysis of 33
uveal melanomas (including nine metastases) described
similar findings with low mutation frequency among
similar genes, although also describing novel mutated
genes such as CSMD1, TTC28, DLK2, and KTN1 at low
frequency [18]. More recently, targeted sequencing of
500 genes in pUM and matched metastases from 35
patients revealed new driver mutations in genes such as
CDKN2A, PBRM1, EZH2, PIK3R2, PIK3CA, PTEN, and
MED12 with clonal and subclonal events [19]. Minimal
data exists surrounding gene expression patterns in metastatic UM (mUM); however, analysis by TCGA primary
tumors suggested four-clusters in pUM that separated
M3- and D3-UM [13]. Pathway profiling of these data
suggested the importance of signatures including DNA
damage response, hypoxia, MYC signaling, and MAPK/
AKT programs differentiated subgroups within both the
M3-UM and D3-UM subgroups.

RNA sequencing of tumor samples

Although current systemic treatments are limited, there
is some suggestion that emerging immune insights [20]
and immuno-therapeutics may have utility [21–23].
Recently, single-cell sequencing of mUM samples suggested a complex landscape of tumor and immune cell
interactions [24,25]. In this context, a better understanding of mUM biology may nominate molecular targets
worth further exploration. Here, we investigated gene
expression patterns in metastatic tumor specimens from

Methods
Tumor sample collection

Nineteen formalin-fixed paraffin-embedded (FFPE)
metastatic tumor samples were collected and analyzed
(Supplementary Table 1, Supplemental digital content
1, http://links.lww.com/MR/A245). Tumor percentage per
sample was graded by a pathologist (T.C.) for 15 out of
19 samples, where sufficient tumor tissue remained after
nucleic acid extraction. On average, 66% tumor content
was observed per sample.
Total RNA was isolated from tumor FFPE tissue sections
using QIAGEN Allprep DNA/RNA FFPE kit (Qiagen,
Inc.) according to manufacturer’s instruction at the Human
Immunologic Monitoring Facility at the University of
Chicago. The quality and quantity of RNA was measured
on an Agilent 2100 Bio-analyzer using Agilent reagents
and protocols (Agilent Technologies, Santa Clara, USA).
RNAseq libraries were generated using Illumina TruSEQ
Total RNA stranded library making kits using Illumina
protocols (Illumina, San Diego, USA). The quality and
quantity of the library was determined using an Agilent
2100 Bio-analyzer using Agilent reagents and protocols.
RNAseq libraries were sequenced on an Illumina HiSeq
4000 instrument using Illumina reagents and protocols at
the University of Chicago Genomics Core Facility.
Gene expression quantification and differential gene
expression detection

The quantification of gene-level expression and detection of differentially expressed genes (DEGs) were performed using a protocol similar as previously published
[26]. In brief, the quality of raw reads was assessed by
FastQC (v0.11.5) [27]. Transcript-level read counts were
quantified by Kallisto (v0.44.0) [28] in a strand-specific
mode with GENCODE [29] annotation of human reference transcriptome (v28, GRCh38). Kallisto implements
a kmer-based pseudoalignment algorithm to accurately
quantify transcripts from RNASeq data while robustly
detecting errors in the reads. Transcript-level abundance
was summarized into gene level by tximport (v1.4.0)
[30], normalized by trimmed mean of M values (TMM)
method, and log2-transformed. Out of 19 883 protein-coding genes in total, 14 307 genes that are expressed
[defined as, counts per million of reads > 3] in at least
six samples were kept for further analysis. Genes differentially expressed between groups were identified using
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limma voom algorithm with precision weights (v3.38.3)
[31], followed by Benjamini-Hochberg (BH)-FDR correction for multiple testing [32].
Gene set enrichment analysis

Gene set enrichment analysis (GSEA) was performed
by fGSEA (v1.8.0) [33]. The human Hallmark (H) gene
sets from the Molecular Signatures Database (MSigDB)
(v6.2) [34] was used for analyzing the full list of 14 307
genes from the differential gene expression analysis.
Genes were preordered by the log2-transformed expression fold change metrics (log2FC). Enrichment nominal
P-values were calculated by permutation test (10 000
permutations), with BH-FDR correction for multiple
testing [32]. Enrichment score was computed same as
in Broad GSEA implementation [34], and normalized
enrichment score was computed by normalizing enrichment score to mean enrichment of random samples of
the same size [33].
The Cancer Genome Atlas primary cancer cohorts

Raw sequencing FastQ files of tumor RNAseq data were
downloaded from TCGA pUM cohort (primary tumors,
n = 80) using the Genomic Data Commons data portal
(https://portal.gdc.cancer.gov/) (accessed 9/17/2018).
Demographic and clinical data of pUM were obtained
from supplementary tables of the published TCGA study
[13]. All RNAseq data were harmonized using the same
analysis pipelines described above.
Survival analysis

The significance of association between molecular markers and patients’ overall survival (OS) was tested by Cox
proportional hazard univariable or multivariable model
using coxph function from R library survival (v2.42-3),
which also estimates hazard ratio between patient groups.
Patients alive upon last follow-up were censored.
Cell culture

Mel290 and OCM3 were received from Robert Folberg
in 2009 (University of Illinois, Chicago, IL). Mel285
and OMM1.3 were kindly provided by Boris Bastian in
2010 (Memorial Sloan-Kettering Cancer Center, New
York, NY). Mel290, Mel285, and OCM3 were established
from primary tumors by Bruce Ksander (Schepens Eye
Research Institute, Boston, MA) [35]. OMM1.3 was established from liver metastases also by Bruce Ksander [36].
OCM3 uveal melanoma cell lines have been sequenced
for the presence of activating mutations in codons 209
(exon 5) and 183 (exon 4) of GNAQ and GNA11. OMM1.3
had GNAQ mutation while Mel290, Mel285, and OCM3
are wild-type for the gene. A karyotype test was also performed for each cell line in 2012. Cells were cultured in
RPMI medium supplemented with 10% FBS, 100 units/
ml penicillin, and 100 mg/ml streptomycin and maintained at 37°C in 5% CO2.
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Gene silencing

The small interfering RNA (siRNA) sequences for
scramble control (sc-37007) and NRP1 (sc-36038) were
purchased from Santa Cruz Biotechnology (Dallas, TX).
NRP1 siRNA was a pool of three siRNA duplexes:
5′-GAAGGCAGACAGAGAUGAA-3′
5′-CGAGACAGUCCAUUCAUCU-3′
5′-GAAGGAAAGCACUAAGAAA-3′
Mel290, Mel285, OMM1.3, and OCM3 cells were plated
on 60-mm plates, and transfected with scramble control or NRP1 siRNA using Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. The transfections were performed twice,
each time in overnight incubations with a recovery phase
of 6 h in between transfections.
Quantitative real-time PCR

Total RNA was harvested from cells transfected with
either scramble control or NRP1 siRNA using PureLink
RNA Mini Kit (Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions. cDNA was then synthesized from 1 µg total RNA using SuperScript IV FirstStrand Synthesis System (Invitrogen, Carlsbad, CA).
TaqMan mutation detection assays specific for NRP1
primer-probe set (Applied Biosystems, Foster City,
CA) were used to quantitate mRNA expression of target genes normalized to GAPDH. Quantitative real-time
PCR (qRT-PCR) assays were done using the 7500 RealTime PCR System (Applied Biosystems, Foster City,
CA). The relative quantity of genes was determined by
the ΔΔCT method.
Immunoblotting

Cells transfected with either scramble control or
NRP1 siRNA were lysed with radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor cocktail tablets (Roche Diagnostics)
and 1 mmol/l Na3VO4. Equal amounts of protein were
loaded on 4–12% PAGE gels (Invitrogen, Carlsbad, CA).
Polyvinylidene difluoride (PVDF) membranes were
blocked with 5% nonfat dried milk and probed with
NRP1, GAPDH (Cell Signaling Technology, Danvers,
MA), and p27Kip1 (Santa Cruz Biotechnology, Dallas, TX)
antibodies.
Flow cytometry

Cells transfected with either scramble control or NRP1
siRNA were washed and fixed in ice-cold 70% ethanol before staining with propidium iodide (50 μg/
ml) containing RNase (5 μg/ml) to measure DNA content. Samples were sorted using LSR II Cell Analyzer
(BD Biosciences, Franklin Lakes, NJ) for cell-cycle
distribution and analyzed using the FCS Express 6
software. A total of 10 000 events were examined per
sample.
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Fig. 1

Transcriptional programs associated with overall survival in primary uveal melanoma (pUM) from The Cancer Genome Atlas (TCGA). (a) Kaplan–
Meier survival curves of MTORC1 signaling and IL6/JAK/STAT3 signaling gene expression in pUM, split by median expression of each signature
(high vs. low). Survival risk table is shown below the Kaplan–Meier plot in each panel. (b) Forest plots showing the hazard ratio and P-values in
Cox proportional hazards (PHs) multivariable model of the signaling pathways with demographic and clinical covariates. n = 80 patients in the
TCGA primary UM cohort were shown for (a) and (b). Log-rank test was used in (a), and Cox PH multivariable model was used in (b).

Cell viability assays

Cells transfected with either scramble control or NRP1
siRNA were plated in 96-well plates in triplicates.
Viability was assessed after 72 h of treatment using the
Cell Counting Kit 8 (CCK8) from Dojindo Molecular
Technologies (Rockville, MD) according to the manufacturer’s instructions. Survival is expressed as a percentage
of untreated cells.
Cell invasion assays

Cells transfected with either scramble control or NRP1
siRNA were seeded in triplicates for 24 h in media with

0.1% serum on BioCoat Matrigel Invasion Chambers (BD
Biosciences, San Jose, CA) according to manufacturer’s
instructions. RPMI medium with 10% serum was used as
chemoattractant. Noninvading cells were then removed
from the matrigel and cells on the other side of the matrix
were fixed with 100% methanol and stained with 1%
Toluidine Blue. Images of stained cells were obtained
from three random sections of each matrigel to account
for cell distribution. Invading cells were then quantified
by adding cells from the three sections and calculating
the mean of each triplicate. Cell invasion is expressed as
the number of cells migrated.
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Statistics

For the analysis of gene signature expression between
groups, two-sided Student’s t-test was used. Differential
gene expression comparison between groups was performed using linear regression models implemented in
limma voom with precision weights [31]. For multiple
comparisons, P-value was adjusted using BH-FDR correction for multiple testing [32]. Statistical analysis was
performed using R (v3.5.1) and Bioconductor (release
3.8). qPCR experiment was performed twice, and all in
vitro experiments were carried out three times; P-values
were calculated using two-sided Student’s t-test, standard error was calculated as the SD divided by the square
root of the number of samples.
Study approval

Tumor samples were collected within the context of
Alliance for Clinical Trials in Oncology A091201 [16],
which was reviewed and approved by the NCI Central
Institutional Review Board (CIRB) or the IRB of
each participating site (ClinicalTrials.gov Identifier:
NCT01835145). Each participant signed an IRBapproved, protocol-specific informed consent document
in accordance with federal and institutional guidelines.

Results
Association of transcriptional programs with survival in
uveal melanoma

Uveal melanoma has previously been described as a
relatively simple genomic disease characterized by four
overarching molecular subtypes [13]. Given the lack
of therapeutic options for treatment of advanced disease, we were interested in investigating pathways and
potential therapeutic targets that might be relevant to
survival outcomes. To pursue this, we analyzed the association between cancer-associated signaling pathways
and survival in the pUM cohort from TCGA. To reduce
false discovery rate, we focused on 50 curated gene sets
representative of cancer-associated pathways defined
by human Hallmark (H) category from the Molecular
Signatures Database (MSigDB; v6.2) (Supplementary
Table 2, Supplemental digital content 1, http://links.lww.
com/MR/A245). One score was assigned to each gene
set by taking the average of expression across all genes
involved in that gene set, and then testing for significant associations with OS. Using Cox proportional hazard univariable models, we observed higher expression
score of 18 gene sets significantly associating with longer
OS (FDR-adjusted P < 0.05; Supplementary Table 3,
Supplemental digital content 1, http://links.lww.com/MR/
A245). Using multivariable models, after adjusting for
covariates including demographic factors (age and gender) and previously reported significant clinical variables from TCGA (histology and pigmentation) [13],
we observed top gene sets (ranked by P-value from
low to high) of MTORC1 signaling, glycolysis, PI3K/
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AKT/MTOR signaling, and IL6/JAK/STAT3 signaling
(Supplementary Table 3, Supplemental digital content
1, http://links.lww.com/MR/A245). As the first three gene
sets share some degree of functional redundancy, Fig. 1a
conveys the impact of MTORC1 signaling as an example
as well as the other distinct pathway of IL6/JAK/STAT3
signaling. The adjusted P-values and HRs for gene sets
of interest and covariates are shown in Fig. 1b. Results of
glycolysis and PI3K/AKT/MTOR signaling are provided
in Supplementary Figure 1, Supplemental digital content
1, http://links.lww.com/MR/A246. As previous studies have
suggested that pUM can be categorized into low-risk
(Disomy 3, D3) and high-risk (Monosomy, M3) groups
based on genomic signatures [13], we repeated the same
analysis within the high-risk M3 group (42/80 patients),
and observed no gene sets demonstrating significant
association with OS by cox proportional hazard univariable or multivariable models at FDR-adjusted P < 0.05
(Supplementary Table 3, Supplemental digital content 1,
http://links.lww.com/MR/A245).
Epithelial-mesenchymal transition signature separates
1-year overall survival in metastatic uveal melanoma

We recently completed a prospective phase II study in
metastatic uveal melanoma demonstrating no difference
in outcome between cabozantinib and chemotherapy
(Alliance for Clinical Trials in Oncology A091201) [16].
From this study, we obtained adequate pretreatment
tissue from a group of patients (n = 19) and pursued
RNAseq analysis. To identify the molecular factors associated with survival in mUM, we investigated the 50
transcriptional programs outlined above comparing OS,
as the time from the start of treatment in the trial until
death from any cause, in A091201 [16]. Using Cox proportional hazard univariable model, EMT was the top
gene program associated with OS ranked by P-values
(P = 0.02), with higher EMT expression score predicting
worse outcome (Supplementary Table 4, Supplemental
digital content 1, http://links.lww.com/MR/A245). This
association lost significance after adjusting for multiple
testing correction (FDR-adjusted P = 0.61), potentially
due to small size. Considering these findings from a clinical context, we then split patients into two groups centered on 1 year of survival from starting treatment on
the clinical trial (Supplementary Figure 2, Supplemental
digital content 1, http://links.lww.com/MR/A246), observing that patients with OS ≤ 1 year showed higher expression of the EMT gene expression signature (P = 0.15,
Student’s t-test, two-sided) (Fig. 2a). Considering the
OS is a time-to-event endpoint, we next tested the association between EMT gene signature expression as a
continuous variable in Cox proportional hazard univariable model of OS and observed a significant association
(P = 0.046, HR = 2.45) (Fig. 2b). Taking together, these
data suggested that EMT may be a prognosis predictor
in mUM.
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Fig. 2

Epithelial-mesenchymal transition (EMT) signature is significantly associated with overall survival (OS) in patients with metastatic uveal melanoma.
(a) Expression of the EMT gene signature in patient survival groups split by 1-year OS; n = 14 in patients with OS ≤ 1 year, n = 5 in patients with
OS > 1 year. (b) Kaplan–Meier survival analysis of OS in patients with tumors EMThigh and EMTlow, split by median expression of the EMT gene
signature. Nineteen patients were shown in (a) and (b), split by two different metrics [1-year OS in (a), and median EMT expression in (b)]. Survival
risk table is shown below the plot. Two-sided Student’s t-test was used in (a). Cox proportional hazards univariable model was used in (b).

Patients with overall survival of less than 1 year
demonstrated differential gene expression including
expression of NRP1

Cognizant of the lack of effective systemic therapeutic
options for patients facing mUM, we were interested to
investigate possible targets associated with differential
survival outcomes observed in A091201. To pursue this,
we initially compared the whole transcriptome profiles
of patients with OS ≤ 1 year to those with OS > 1 year.
We ranked individual genes by P-value smaller to larger
and selected top DEGs at P < 0.005 (unadjusted) and
fold change ≥2.0 or ≤ –2.0 (Fig. 3a). A total of 76 genes
passed the threshold, with 22 upregulated in patients
who lived less than 1 year (Fig. 3b; Supplementary
Table 5, Supplemental digital content 1, http://links.lww.
com/MR/A245). Among those, NRP1, encoding a transmembrane glycoprotein neuropilin-1 that binds various
vascular endothelial growth factor isoforms and TGFβ,
has been shown to be associated with EMT in multiple tumor types [37–40]. Additionally, previous [41] and
on-going clinical trials (clinicaltrials.gov: NCT03565445)
are investigating monoclonal antibodies targeting neuropilin-1, raising therapeutic interest. Considering the
overall lower tumor purity in the metastatic samples from
A091201 compared to primary tumors from TCGA, we
sought to confirm that differences observed in NRP1
gene expression were not due to tumor purity differences
between groups and observed no significant tumor purity

differences between mUM patient OS groups (P = 0.182,
Student’s t-test, two-sided). Collectively, these analyses
suggest expression of NRP1 in patients with OS > 1 year
may represent disease-specific biological context.
To confirm our analysis by an orthogonal approach, we
additionally investigated the overall pattern of signaling
pathway changes between the two OS groups utilizing the
full list of genes without P-value or fold change cutoffs.
We calculated enrichment scores and significance level of
50 HALLMARK gene sets from MSigDB database. EMT
genes and IL6/JAK/STAT3 signaling genes were identified to be significantly enriched and activated in patients
with OS ≤ 1 year relative to >1 year (FDR-adjusted
P < 0.05) (Supplementary Figure 3, Supplemental digital content 1, http://links.lww.com/MR/A246). This result
supports our findings above investigating association
between gene sets and survival using Cox proportional
hazard analysis. Despite no genes passing FDR-adjusted
P < 0.05 in multivariable models previously, we subsequently demonstrate that using the GSEA approach, the
same transcriptional programs are significantly enriched
in tumors from patients who lived less than 1 year.
Knockdown of NRP1 gene expression in vitro induces
G1 arrest and inhibits cell proliferation and invasion

Observing association between NRP1 expression and
OS < 1 year, we were interested to assess the functional
impact of blocking NRP1 in uveal melanoma cells. To
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Fig. 3

Differentially expressed genes of metastatic uveal melanoma in patient survival groups split by 1-year overall survival (OS). (a) Expression heatmap
of 76 differentially expressed gens (DEGs) comparing tumors from patients who lived less than 1 year to those who lived longer. Genes were
filtered by P < 0.005 (unadjusted) and fold change ≥2.0 or ≤–2.0. Samples were clustered on the column with dendrogram shown above the
heatmap. Annotation bar labels patient groups with OS ≤ or >1 year. Genes are shown in the boxes to the right of the heatmap, following the
same order as the gene dendrogram to the left side of the heatmap. (b) Expression of 22 DEGs upregulated in tumors from patients with OS ≤ 1
year relative to those with OS > 1 year. FC = expression fold of change calculated by comparing patients with OS >1 year to patients with OS ≤1
year. 1 yr = one year. The limma voom regression model with precision weights was used in (a) and (b).
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Fig. 4

Knockdown of neuropillin-1 (NRP1) gene expression in vitro induces G1 arrest and inhibits cell proliferation and invasion. (a) NRP1 mRNA
expression in uveal melanoma cell lines Mel290, Mel285, OMM1.3, and OCM3. n = 2 in each of the four cell lines, quantitative PCR was
performed in triplicates, experiment was repeated two times. (b) Western blots of Mel290, Mel285, OMM1.3, and OCM3 cells transfected
with NRP1 small interfering RNA (siRNA) shows inhibition of NRP1 expression and induction of p27Kip1 expression. (c) Cell cycle analysis
of uveal melanoma cells transfected with NRP1 siRNA for 72 h shows a significant increase in G1 population in Mel290 (P < 0.0001) and
Mel285 (P = 0.035) cells but not OMM1.3 and OCM3 cells; n = 3 in each of the four cell lines, with two groups each, experiment was repeated
three times. (d and e) The siRNA knockdown of NRP1 expression significantly inhibits cell viability (d) after 72 h (Mel290 P = 0.009, Mel285
P = 0.003, OMM1.3 P = 0.18, OCM3 P < 0.001) and cell invasion (e) after 24 h of uveal melanoma cells that highly express NRP1 (Mel290 and
Mel285). In (d), n = 3 in each of the four cell lines, with two groups each, experiment was repeated three times. (f) Quantitation of migrated cells
shows the selective inhibition of invasion by NRP1 siRNA knockdown in Mel290 (P = 0.046) and Mel285 (P = 0.007) cells but not OMM1.3
(P = 0.40) and OCM3 (P = 0.42) cells. n = 3 in each of the four cell lines, with two groups each, experiment was repeated three times. In (c), (d),
and (f), each bar is shown as mean ± S.E.M, with standard error calculated as the SD divided by the square root of the number of samples. Twosided Student’s t-test was used in (c), (d), and (f); ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.

pursue this, we initially evaluated the gene expression of
NRP1 in several uveal melanoma cell lines and identified
at least two NRP1 expressing cell lines (Mel290, Mel285),

and two with relatively low NRP1 mRNA expression
(OMM1.3, OCM3) (Fig. 4a). Western blot analysis of
uveal melanoma also showed greater protein expression
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of NRP1 in Mel290 and Mel285 relative to OMM1.3 and
OCM3 (Fig. 4b). NRP1 has been shown to stimulate
GIPC1 and Syx complex formation and activating RhoA
thus inducing p27Kip1 degradation and that suppression
of NRP1 expression by siRNA results in increased p27Kip1
expression [42]. In our study, siRNA knockdown of NRP1
markedly induced p27Kip1 expression compared to the
scramble transfected control. Since p27Kip1 is induced by
NRP1 suppression, we conducted a cell cycle analysis of
uveal melanoma cells transfected with scramble control or
NRP1 siRNA (Fig. 4c). We found that NRP1 suppression
for 72 h significantly induced G1 arrest in Mel290 and
Mel285 cells (P < 0.0001 and P < 0.05, respectively) while
cells that do not express NRP1, OMM1.3 and OCM3
were not affected, when compared to scramble controls.
Similarly, in viability assays, NRP1 siRNA for 72 h significantly inhibited cell proliferation in NRP1 expressing cell lines Mel290 (P = 0.009) and Mel285 (P = 0.003)
(Fig. 4d). In contrast, NRP1 downregulation induced
lesser effects in cells with low expression of NRP1, as cell
viability was slightly reduced in OCM3 cells (P < 0.001)
or increased in OMM1.3 cells (P = 0.18) (Fig. 4d). In cell
invasion assays through matrigel, NRP1 siRNA knockdown significantly suppressed cell migration of Mel290
(P < 0.05) and Mel285 (P < 0.01) but not OMM1.3 and
OCM3 after 24 h (Fig. 4e and f), conditions under which
cell viability is not affected (data not shown).

Discussion

Treatment options for patients with mUM are limited
and outcomes are poor emphasizing a high, unmet need
for patients facing this rare disease [1]. While the biology
of pUM is increasingly understood through efforts such
as TCGA, comparatively less has been known about metastatic disease. In our transcriptional analysis of patient
samples derived from a prospective clinical trial, we
identify transcriptional signatures associated with patient
survival in metastatic disease and a number of DEGs
associated with poor outcomes. Of these, NRP1 may
be especially interesting as knockdown experiments in
uveal melanoma cells suggest a functional role in proliferation, migration, and other processes relevant to metastasis and cancer progression in mUM.
We initiated our analysis focusing on pUM via analysis
of TCGA observing growth signals through PI3K/mTOR
and IL6 signaling being associated with progression
and death from primary lesions. Multiple studies have
described pUM as paradoxically demonstrating a tumor
microenvironment densely packed by immune cells [1];
however, large-scale sequencing efforts also suggest the
majority of pUM lack an active tumor microenvironment
or T cell-inflamed phenotype [43]. Relevant to this, signaling through the PI3K cascade has been associated with
immuno-suppression [44] and despite the lack of genomic
alterations observed in pUM, transcriptional activation
through PI3K may be driving this phenotype as has been
described for other oncogenes such as β-catenin [45].
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Additionally, the tumor microenvironment of pUM has
been described as macrophage rich [1] and our finding
of IL6-associated pathway activation is consistent with
this. Considering these findings, it may be interesting to
speculate on the utility of PI3K or mTOR inhibitor having a potential adjuvant role for patients with pUM after
definitive therapy to limit metastasis and eventual death
from disease.
Our analysis of transcriptional programs from patients
with mUM suggests a potentially important role for
EMT programs in dictating survival outcomes for this
population of patients. An impact of EMT on survival in
patients with metastatic cancer has been described across
multiple tumor settings [46], although it previously had
not been described in tumors from patients with mUM.
Identification of the EMT process in uveal melanoma is
potentially of relevance toward drug development and
clinical trials, as approaches targeting EMT-related molecules such as β-catenin, TGF-β, and MYC have not been
previously prioritized. It is also potentially noteworthy
that EMT or stem-like states have been linked to the
non-T-cell-inflamed tumor microenvironment and resistance to cancer immunotherapy [20,45,47,48]. In this setting, inhibitors of EMT may be useful as combination
partners for immunotherapy, especially in mUM.
Our analysis of DEGs, in the context of patient survival,
nominated a group of potentially intriguing genes that
might be explored as therapeutic targets. While it should
be noted that the sample size of the analysis was relatively small, mUM is an orphan disease and this is one of
the first reports of transcriptional data from human tumor
samples collected in a clinical trial. In our analysis, we
observed that expression of NRP1 was associated with
survival of patients of less than 1 year. NRP1 is particularly interesting as it has well-described functions relating
to angiogenesis [49], EMT [37] as well as immune-modulation of Treg cells [50] and M2 macrophages [51]. Here,
we particularly observed a cell-intrinsic role for NRP1 in
regulating uveal melanoma proliferation, viability, and
invasion, which could be reversed with NRP1 siRNA
exposure in cell line experiments. A previous generation of anti-NRP1 monoclonal antibodies was brought
unsuccessfully into cancer clinical trials in attempts to
target angiogenesis in advanced solid tumors [41]. More
recently, a new generation of NRP1 antibodies, including
ASP1948 and others, has come forward with intent to be
used as checkpoint blocking antibodies either alone or
with anti-PD1 agents. These data suggest that consideration of a clinical trial in mUM might be prioritized.
We acknowledge that there are limitations to our report.
As a rare cancer, investigation of patient-derived biospecimens of mUM is inherently limited by sample size.
The tumor samples analyzed here were obtained in the
context of a National Clinical Trials Network clinical
trial (A091201) in which diagnostic tumor samples were
obtained predominantly from the community practice
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setting. While extremely valuable, this approach has the
potential to limit sample quality and limits the discovery power for differential gene expression analysis (e.g.
multiple testing correction). This approach also eliminates the availability of further tissue to do confirmatory protein-based studies (e.g. immunohistochemistry).
Obtaining biospecimens in this manner does have the
utility of facilitating prospective clinical annotation and
limiting the biases surrounding analysis of samples collected and analyzed in retrospective cohorts.
In summary, we have performed a transcriptional analysis of human mUM and observed novel associations with
survival in the metastatic setting. We identified from the
prospective clinical trial A091201 an impact of EMT on
survival and both nominated and performed preliminary
functional validation of NRP1 as a potential therapeutic
target. These results immediately suggest avenues for
novel investigation and clinical trials for patients with
metastatic uveal melanoma. ClinicalTrials.gov Identifier:
NCT01835145.
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